Quantum Biopharma Ltd.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2025 · Filed Mar 26, 2026

QNTM$2.11-0.2%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Cover page INTRODUCTION CAUTIONARY NOTE REGARDING FUTURE ORIENTED FINANCIAL INFORMATION MARKET AND INDUSTRY DATA SUMMARY RISK FACTORS Item 1. Identity of Directors, Senior Management and Advisers

Item 2. Offer Statistics and Expected Timetable (no text here)

Item 3. Key Information

D. Risk Factors

Item 4. Information on the Company

A. History and Development of the Company B. Business Overview C. Organizational Structure D. Property, Plants and Equipment

Item 4A. Unresolved Staff Comments (no text here)

Item 5. Operating and Financial Review and Prospects

A. Operating Results B. Liquidity and Capital Resources C. Research and Development, Patents and Licenses, etc D. Trend Information E. Critical Accounting Estimates

Item 6. Directors, Senior Management and Employees

A. Directors and Senior Management B. Compensation C. Board Practices D. Employees E. Share Ownership

Item 7. Major Shareholders and Related Party Transactions

A. Major Shareholders B. Related Party Transactions

Item 8. Financial Information

A. Consolidated Statements and Other Financial Information B. Significant Changes

Item 9. The Offer and Listing

A. Offer and Listing Details C. Markets

Item 10. Additional Information

B. Memorandum and Articles of Association C. Material Contracts D. Exchange Controls E. Taxation H. Documents on Display Item 11. Quantitative and Qualitative Disclosures About Market Risk

Item 12. Description of Securities Other than Equity Securities

D. American Depositary Shares

Item 13. Defaults, Dividend Arrearages and Delinquencies (no text here)

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds

Item 15. Controls and Procedures

A. Disclosure Controls and Procedures B. Management’s Annual Report on Internal Control over Financial Reporting D. Changes in Internal Control Over Financial Reporting Item 16A. Audit Committee Financial Expert Item 16B. Code of Ethics Item 16C. Principal Accountant Fees and Services

Item 16D. Exemptions from the Listing Standards for Audit Committees (no text here)

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Item 16F. Change in Registrant’s Certifying Accountant (no text here)

Item 16G. Corporate Governance

Item 16H. Mine Safety Disclosure (no text here)

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections (no text here)

Item 16J. Insider Trading Policies Item 16K. Cybersecurity

Item 17. Financial Statements (no text here)

Item 18. Financial Statements Item 19. Exhibits

B. Significant Changes

A discussion of the significant changes in our business can be found under “Item 4. Information on the Company—A. History and Development of the Company” and “Item 4. Information on the Company—B. Business Overview.”

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.